Stockreport

US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk

GSK plc American Depositary Shares (Each representing two Ordinary Shares)  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1Clinical development program continues to evaluate s [Read more]